BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/28/2020 10:02:57 AM | Browse: 70 | Download: 42
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 47888
Country of Manuscript Source Greece
2019-03-29 01:49
Peer-Review Started
2019-04-03 08:28
To Make the First Decision
Return for Revision
2019-11-11 21:28
2019-11-28 06:15
Second Decision
2019-12-13 11:27
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-12-15 05:53
Articles in Press
2019-12-15 05:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-12-20 01:42
Publish the Manuscript Online
2020-02-15 12:32
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Manuscript Source Invited Manuscript
All Author List Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G Papavassiliou and Michalis V Karamouzis
Funding Agency and Grant Number
Corresponding author Michalis V Karamouzis, MD, PhD, Associate Professor, Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75, M. Asias Street, Athens 11527, Greece. mkaramouz@med.uoa.gr
Keywords Pancreatic ductal adenocarcinoma; Tumor microenvironment; Immunotherapy; Gemcitabine; Treatment; Cancer stem cells
Core Tip Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Treatments such as surgery, radiation, and chemotherapy have limited efficacy due to the extensive heterogeneity of genetic mutations and the dense stromal environment, among other causes. In recent years, immunotherapy has been successfully applied in the treatment of various types of cancers, and immunotherapy combined with the above treatments could create more favorable conditions for the fight against PDAC.
Publish Date 2020-02-15 12:32
Citation Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 2020; 12(2): 173-181
Url https://www.wjgnet.com/1948-5204/full/v12/i2/173.htm
DOI https://dx.doi.org/10.4251/wjgo.v12.i2.173
Full Article (PDF) WJGO-12-173.pdf
Full Article (Word) WJGO-12-173.docx
Manuscript File 47888-Review.docx
Answering Reviewers 47888-Answering reviewers.pdf
Audio Core Tip 47888-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 47888-Conflict-of-interest statement.pdf
Copyright License Agreement 47888-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 47888-Language certificate.pdf
Peer-review Report 47888-Peer-review(s).pdf
Scientific Misconduct Check 47888-Scientific misconduct check.pdf
Scientific Editor Work List 47888-Scientific editor work list.pdf